Without published research, scientists and prospective investors and customers have little to go on to evaluate a startup’s marketing claims, the Stanford team maintains.
After Theranos, Healthcare Startups Still Aren’t Publishing Enough Peer-Reviewed Research, Says One Stanford Professor. Venture Capitalists Disagree.
